← back to search

Marius Trøseid

Oslo University Hospital · NO
Area of research
Molecular Biology · Emergency Medicine
Research interest
Research interests include Gut microbiota and health, HIV-related health complications and treatments, HIV Research and Treatment, and COVID-19 Clinical Research Studies.
h-index
40
citations
7,005
works
232
NIH funding
primary concept
Medicine
email

Recent publications

Long-term HIV-1 remission achieved through allogeneic haematopoietic stem cell transplant from a CCR5Δ32/Δ32 sibling donor.
2026cited by 0position: contributordoi
Disruption of the Host-Microbiota-Vitamin B6 Tryptophan Axis in Acute COVID-19 and Persistent Pulmonary Impairment
2026cited by 0position: contributordoi
Host Plasma Microenvironment in Immunometabolically Impaired HIV Infection Leads to Dysregulated Monocyte Function and Synaptic Transmission <i>Ex Vivo</i>
Advanced Science 2025cited by 7position: middledoi
Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trial
eBioMedicine 2025cited by 6position: contributordoi
Cytomegalovirus Antibodies and Coronary Artery Disease in People with HIV: A Cohort Study.
2025cited by 2position: contributordoi
Microbial-derived imidazole propionate links the heart failure-associated microbiome alterations to disease severity.
2024cited by 28position: contributordoi
Gut Microbiota Alterations and Circulating Imidazole Propionate Levels Are Associated With Obstructive Coronary Artery Disease in People With HIV
The Journal of Infectious Diseases 2024cited by 16position: contributordoi
Chronic HIV Infection Increases Monocyte NLRP3 Inflammasome-Dependent IL-1α and IL-1β Release.
2024cited by 4position: contributordoi
The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis.
2024cited by 3position: contributordoi
Viral, Host Factors or Both as COVID-19 Biomarkers.
2024cited by 1position: contributordoi
IL-22 is increased in hospitalized patients with COVID-19 and associates with cardiac involvement.
2024cited by 1position: contributordoi
Author Correction: Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer.
2024cited by 0position: contributordoi
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
Critical Care 2023cited by 47position: firstdoi
Microbiome-derived cobalamin and succinyl-CoA as biomarkers for improved screening of anal cancer.
2023cited by 19position: contributordoi
Coronary Artery Disease in Persons With Human Immunodeficiency Virus Without Detectable Viral Replication
Open Forum Infectious Diseases 2023cited by 9position: contributordoi
Fatty Acids Composition and HIV Infection: Altered Levels of n-6 Polyunsaturated Fatty Acids Are Associated with Disease Progression.
2023cited by 5position: contributordoi
Phenylacetylglutamine From the Gut Microbiota: A Future Therapeutic Target in Heart Failure?
2023cited by 4position: contributordoi
Neutrophil count predicts clinical outcome in hospitalized COVID-19 patients: Results from the NOR-Solidarity trial.
2022cited by 13position: contributordoi
Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: Results from two Norwegian cohort studies.
2022cited by 10position: contributordoi
Remdesivir modifies interferon response in hospitalized COVID-19 patients.
2022cited by 1position: contributordoi
Microbiome-Derived Cobalamin and Succinyl-CoA are Powerful Biomarkers for Improved Screening of Anal Cancer
2022cited by 1position: contributordoi
CXCL16 associates with adverse outcome and cardiac involvement in hospitalized patients with Covid-19.
2022cited by 1position: contributordoi
Evaluation of the Effects of Remdesivir and Hydroxychloroquine on Viral Clearance in COVID-19 : A Randomized Trial.
2021cited by 89position: contributordoi
Elevated markers of gut leakage and inflammasome activation in COVID-19 patients with cardiac involvement.
2021cited by 73position: contributordoi
Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections.
2021cited by 28position: contributordoi
Gut Leakage Markers in Response to Strenuous Exercise in Patients with Suspected Coronary Artery Disease.
2021cited by 10position: contributordoi
Gut microbiota alterations in patients with persistent respiratory dysfunction three months after severe COVID-19
2021cited by 0position: contributordoi
Fecal microbiota transplantation in systemic sclerosis: A double-blind, placebo-controlled randomized pilot trial
PLoS ONE 2020cited by 69position: middledoi
Gut microbiota diversity predicts immune status in HIV-1 infection
AIDS 2015cited by 316position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 23 papers (2021–2026)Bente Halvorsen · Harvard University8 papers (2022–2026)Johannes R. Hov · University of Milano-Bicocca7 papers (2022–2026)Tuva B. Dahl · Universidad Pablo de Olavide4 papers (2022–2026)Pål Aukrust · Institutt for Eksperimentell Medisinsk Forskning4 papers (2022–2024)Thor Ueland · Stavanger University Hospital3 papers (2023–2026) · 3 papers (2022–2024)Klaus Fuglsang Kofoed · Charité - Universitätsmedizin Berlin3 papers (2023–2025)Alfonso Muriel · Instituto Ramón y Cajal de Investigación Sanitaria3 papers (2022–2024) · 3 papers (2022–2024) · 3 papers (2023–2025)Andreas Fuchs · Nordsjællands Hospital3 papers (2023–2025)Thomas Benfield · University of Winchester3 papers (2023–2025)Rosa del Campo · Centre for Biomedical Network Research on Rare Diseases3 papers (2022–2024)Anne Margarita Dyrhol-Riise · University of Bergen3 papers (2024–2026)José A. Pérez‐Molina · Instituto Cajal3 papers (2022–2024)Lars Køber · Nordsjællands Hospital3 papers (2023–2025)Sergio Serrano‐Villar · Instituto Cajal3 papers (2022–2024)Johannes R. Hov · Oslo University Hospital2 papers (2015–2020)Susanne Dam Nielsen · Copenhagen University Hospital2 papers (2023–2025)